These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 25242081)

  • 1. Epigallocatechin-3-gallate potentiates the effect of curcumin in inducing growth inhibition and apoptosis of resistant breast cancer cells.
    Wang S; Chen R; Zhong Z; Shi Z; Chen M; Wang Y
    Am J Chin Med; 2014; 42(5):1279-300. PubMed ID: 25242081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of multidrug resistant in cancer cells by EGCG, tannic acid and curcumin.
    Li H; Krstin S; Wink M
    Phytomedicine; 2018 Nov; 50():213-222. PubMed ID: 30466981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
    Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
    Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amphiphilic Copolymeric Micelles for Doxorubicin and Curcumin Co-Delivery to Reverse Multidrug Resistance in Breast Cancer.
    Lv L; Qiu K; Yu X; Chen C; Qin F; Shi Y; Ou J; Zhang T; Zhu H; Wu J; Liu C; Li G
    J Biomed Nanotechnol; 2016 May; 12(5):973-85. PubMed ID: 27305819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3-NFκB signaling.
    Chung SS; Vadgama JV
    Anticancer Res; 2015 Jan; 35(1):39-46. PubMed ID: 25550533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A P-glycoprotein- and MRP1-independent doxorubicin-resistant variant of the MCF-7 breast cancer cell line with defects in caspase-6, -7, -8, -9 and -10 activation pathways.
    Park SJ; Wu CH; Safa AR
    Anticancer Res; 2004; 24(1):123-31. PubMed ID: 15015586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigallocatechin-3-gallate promotes apoptosis and reversal of multidrug resistance in esophageal cancer cells.
    Liu L; Ju Y; Wang J; Zhou R
    Pathol Res Pract; 2017 Oct; 213(10):1242-1250. PubMed ID: 28964574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigallocatechin gallate (EGCG) suppresses growth and tumorigenicity in breast cancer cells by downregulation of miR-25.
    Zan L; Chen Q; Zhang L; Li X
    Bioengineered; 2019 Dec; 10(1):374-382. PubMed ID: 31431131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
    Wang TX; Yang XH
    Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (-)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells.
    Farabegoli F; Papi A; Orlandi M
    Biosci Rep; 2011 Apr; 31(2):99-108. PubMed ID: 20446926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo reversal of doxorubicin resistance by (-)-epigallocatechin gallate in a solid human carcinoma xenograft.
    Zhang Q; Wei D; Liu J
    Cancer Lett; 2004 May; 208(2):179-86. PubMed ID: 15142676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Y6, an epigallocatechin gallate derivative, on reversing doxorubicin drug resistance in human hepatocellular carcinoma cells.
    Wen Y; Zhao RQ; Zhang YK; Gupta P; Fu LX; Tang AZ; Liu BM; Chen ZS; Yang DH; Liang G
    Oncotarget; 2017 May; 8(18):29760-29770. PubMed ID: 28423656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGCG down-regulates telomerase in human breast carcinoma MCF-7 cells, leading to suppression of cell viability and induction of apoptosis.
    Mittal A; Pate MS; Wylie RC; Tollefsbol TO; Katiyar SK
    Int J Oncol; 2004 Mar; 24(3):703-10. PubMed ID: 14767556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of c-fos by shRNA sensitizes adriamycin-resistant MCF-7/ADR cells to chemotherapeutic agents via P-glycoprotein inhibition and apoptosis augmentation.
    Shi R; Peng H; Yuan X; Zhang X; Zhang Y; Fan D; Liu X; Xiong D
    J Cell Biochem; 2013 Aug; 114(8):1890-900. PubMed ID: 23494858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigallocatechin-3 gallate induces growth inhibition and apoptosis in human breast cancer cells through survivin suppression.
    Tang Y; Zhao DY; Elliott S; Zhao W; Curiel TJ; Beckman BS; Burow ME
    Int J Oncol; 2007 Oct; 31(4):705-11. PubMed ID: 17786300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gambogic acid sensitizes resistant breast cancer cells to doxorubicin through inhibiting P-glycoprotein and suppressing survivin expression.
    Wang S; Wang L; Chen M; Wang Y
    Chem Biol Interact; 2015 Jun; 235():76-84. PubMed ID: 25824409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergism from sequenced combinations of curcumin and epigallocatechin-3-gallate with cisplatin in the killing of human ovarian cancer cells.
    Yunos NM; Beale P; Yu JQ; Huq F
    Anticancer Res; 2011 Apr; 31(4):1131-40. PubMed ID: 21508356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of P-glycoprotein function and reversal of multidrug resistance by (-)-epigallocatechin gallate in human cancer cells.
    Qian F; Wei D; Zhang Q; Yang S
    Biomed Pharmacother; 2005 Apr; 59(3):64-9. PubMed ID: 15795098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced anticancer potency of doxorubicin in combination with curcumin in gastric adenocarcinoma.
    Firouzi Amoodizaj F; Baghaeifar S; Taheri E; Farhoudi Sefidan Jadid M; Safi M; Seyyed Sani N; Hajazimian S; Isazadeh A; Shanehbandi D
    J Biochem Mol Toxicol; 2020 Jun; 34(6):e22486. PubMed ID: 32128952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel and curcumin coadministration in novel cationic PEGylated niosomal formulations exhibit enhanced synergistic antitumor efficacy.
    Alemi A; Zavar Reza J; Haghiralsadat F; Zarei Jaliani H; Haghi Karamallah M; Hosseini SA; Haghi Karamallah S
    J Nanobiotechnology; 2018 Mar; 16(1):28. PubMed ID: 29571289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.